MicroSectors FANG and Innovation 3X Leveraged ETN vs Novavax Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.63 (market cap $2.98B), while Novavax Inc trades at $12.5 (market cap $1.82B). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is the larger of the two by market cap, and Novavax Inc is more actively traded (6,198,505 versus 4,682,352). Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Novavax Inc for 59 Days on average.
| FNGU | NVAX | |
|---|---|---|
Market Cap | $2.98B | $1.82B |
Volume | 4,682,352 | 6,198,505 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $12.56 |
52-Week Low | $13.73 | $6.22 |
Typical Hold Time | 19 Days | 59 Days |
Enterprise Value | — | $1.39B |
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.31, down 2.39% today. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETN faces significant volatility risks, having lost 87% during previous tech sector downturns according to 247 Wallst analysis from August 19, 2026.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest near-term upside potential to resistance at $37-39, the extreme volatility and concentration in mega-cap tech stocks present substantial downside risks during market corrections. Investors require high risk tolerance for this instrument.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →